Find in Library

S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

oleh: Jason Valent, Michaela Liedtke, Jeffrey Zonder, Maria Angelica Molina, Chandrasekhar Udata, Juliana Ianus, John Tripptree, Julia Catini, C Cristina Quarta